Search results
Added:
1 year ago
Added:
6 months ago
SCAI 2025 - Insights from antiplatelet therapy after transcatheter aortic valve replacement (TAVR) show patients who received single antiplatelet treatment had significantly lower rates of overall six-month mortality, CV death and non-CV death compared to those treated with double antiplatelet treatment.Dr Francesco Pelliccia (Sapienza University of Rome, Rome, IT) joins us to discuss insights…
View more
Added:
1 month ago
Added:
1 month ago
Learn about the definition and implications of a shock diagnosis and systems of care and the role of the shock team from Dr Frederick Welt (University of Utah, US).This three-part video lecture series, part of Women As One’s CLIMB® 2025 Skills Training Programme, offers case-based insights into Coronary and Mechanical Support for Cardiogenic Shock, curated by Dr Alison Duncan and Dr Frederick…
View more
Added:
1 week ago
TCT 2025 - Short-term anticoagulation reduced adverse events following left atrial appendage closure (LAAC) compared to dual antiplatelet therapy (DAPT).Dr Josep Rodés-Cabau (Quebec Heart and Lung Institute, Quebec, CA) joins us at TCT 2025 to discuss findings from ANDES trial (NCT03568890) investigating the safety and efficacy of short-term anticoagulation versus DAPT for preventing device…
View more
Evolving Strategies in Pulmonary Embolism: From Risk Stratification to Interventional Therapy
Start date:
Dec 04, 2025
Broadcast
Added:
9 months ago
LINC 2025 - 12-month amputation and readmission rates from the TRUE-PTX study suggests endovascular revascularisation for peripheral artery disease (PAD) with drug-eluting devices lead to better outcomes than with bare device therapies.Dr Marianne Brodmann (Medical University of Graz, AT) joins us to discuss the TRUE-PTX study evaluating a database of patients in the US with PAD who have recieved…
View more
Added:
1 week ago
Source:
Radcliffe Cardiology
The optimal duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) requires a careful balance between reducing ischaemic events and minimising bleeding risk. The HOST-BR trial was designed to evaluate the ideal DAPT duration in patients stratified by their bleeding risk.¹This open-label, multicentre, randomised clinical trial enrolled 4,897 patients who…
View more
Added:
7 months ago
CRT 25 - Outcomes in patients with intermediate-risk pulmonary embolism (PE) with contraindications to thrombolytics show large-bore mechanical thrombectomy is a safe and effective treatment option for this comorbid patient population. In the contraindication cohort, large-bore mechanical thrombectomy was successfully performed with no in-hospital mortality or intracranial haemorrhage.Dr Stefan…
View more
Added:
1 year ago
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter tricuspid valve replacement (TTVR) compared to optimal medical therapy for patients with severe tricuspid regurgitation (TR).Dr Susheel Kodali (Columbia University Medical Center, New York, US) joins us onsite at TCT Conference to discuss the findings from the TRISCEND II Trial (NCT04482062; Edwards Lifesciences).TRISCEND II is a…
View more